Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 20/20 | 0.63 |
| ▸ | GRM5 | P41594 | 6/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8237771 | 0.91 | GRM1 (0.60) | GRM1GRM5KDM4EALDH1A1HTT | |
| SCHEMBL8237288 | 0.90 | GRM1 (0.58) | GRM1GRM5KDM4EALDH1A1HTT | |
| SCHEMBL8276687 | 0.89 | ESR2 (0.56) | GRM1GRM5KDM4EALDH1A1HTT | |
| SCHEMBL8241755 | 0.87 | GRM1 (0.74) | GRM1GRM5 | |
| SCHEMBL8235604 | 0.86 | GRM1 (0.75) | GRM1GRM5KDM4EALDH1A1HTT | |
| SCHEMBL8235641 | 0.81 | GRM1 (0.64) | GRM1GRM5 | |
| SCHEMBL8243296 | 0.80 | GRM1 (0.75) | GRM1GRM5KDM4EALDH1A1HTT | |
| SCHEMBL8276801 | 0.80 | GRM1 (0.75) | GRM1GRM5KDM4EALDH1A1HTT | |
| SCHEMBL13268278 | 0.79 | GRM1 (0.71) | GRM1GRM5KDM4EALDH1A1HTT | |
| SCHEMBL8243855 | 0.79 | GRM1 (0.70) | GRM1GRM5KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1765829-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORP (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598259-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION | 2009-07-30 | — | — | US | disclosed |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | SCHERING CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | SCHERING CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-7485648-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485648-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006002051-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192178-A1 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | GRM1, GRM4, GRIA1 | GRM1 1/4885GRM5 8/4885KDM4E 1129/4885 |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | GRM1 1/4885GRM5 8/4885KDM4E 1129/4885 |
| US-20090082336-A1 | mGluR1 Antagonists as Therapeutic Agents | GRM1, GRM4, GRIA1 | GRM1 1/4885GRM5 8/4885KDM4E 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.